BioRestorative Announces Pricing of $5.0 Million Public Offering

Core Viewpoint - BioRestorative Therapies, Inc. has announced a public offering of 14,285,715 shares of common stock at a price of $0.35 per share, aiming to raise approximately $5.0 million for clinical trials and development projects [1][3]. Group 1: Offering Details - The public offering includes 14,285,715 shares of common stock and warrants to purchase an equal number of shares, priced at $0.35 each [1]. - The warrants will have an exercise price of $0.35 per share, are immediately exercisable, and will expire five years from issuance [1]. - The closing of the offering is expected around February 13, 2026, pending customary closing conditions [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be allocated to clinical trials for BRTX-100, pre-clinical research for the ThermoStem Program, development of a commercial biocosmeceuticals platform, and general corporate purposes [3]. Group 3: Company Overview - BioRestorative focuses on regenerative medicine, particularly stem cell-based therapies, with two main clinical development programs: the Disc/Spine Program and the Metabolic Program [6][7]. - The Disc/Spine Program features BRTX-100, a cell therapy for treating lumbosacral disc disorders, currently in Phase 2 clinical trials [6]. - The Metabolic Program aims to develop therapies targeting obesity and metabolic disorders using brown adipose-derived stem cells [7]. - The company also operates a BioCosmeceutical platform, offering products designed to improve cosmetic appearance through cell-based secretome technology [8].